Autres langues VolitionRx Limited

Actions

VNRX

US9286612067

Recherche biotechnologique et médicale

Marché Fermé - NYSE 22:00:00 30/09/2026			Varia. 5j.	Varia. 1 janv.
0,2580 ^USD	+0,74%		+4,45%	-94,95%

17/09	VolitionRx Limited apporte des précisions sur le lancement officiel du projet DETECSEPS pour le dépistage précoce du sepsis	CI
17/09	Le test Nu.Q NETs de VolitionRx Limited sélectionné comme unique biomarqueur pour la détection précoce du sepsis en France	CI

Autres langues

17/09	VolitionRx Limited Shares Further Details On The Official Launch Of The DETECSEPS Project On The Early Detection Of Sepsis
17/09	Volitionrx Limited Nu.Q Nets Assay Selected as Sole Biomarker for Early Detection of Sepsis in France
17/09	VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
17/09	VolitionRx Participates in Launch of DETECSEPS Program in France
14/09	VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
28/08	VolitionRx Files for Secondary Offering of Common Shares
26/08	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
26/08	Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
13/08	VolitionRX: Q2 Earnings Snapshot
13/08	VolitionRx : Announces Second Quarter 2026 Financial Results and Business Update
13/08	VolitionRx Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
12/08	VolitionRx Limited Demonstrates Utility of Rapid Point-Of-Care Finger-Prick Test in Sepsis Patients
12/08	VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
05/08	VolitionRx Limited Publishes First Peer-Reviewed Paper On Capture-Seq Liquid Biopsy Technology
05/08	Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
30/07	Volitionrx Limited Provides Update on Nu.Q Nets Product Platform and Clinical Evidence
30/07	Volition Advances Nu.Q® NETs Platform Towards Commercialization
25/07	Certain Restricted Stock Units of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 25-JUL-2026.
25/07	Certain Options of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 25-JUL-2026.
25/07	Certain Warrants of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 25-JUL-2026.
25/07	Certain Common Stock of VolitionRx Limited are subject to a Lock-Up Agreement Ending on 25-JUL-2026.
07/07	VolitionRx Limited Releases Data Demonstrating Prognostic Value of Nu.Q Cancer Assay in Newly Diagnosed Lung Cancer Patients
07/07	VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
17/06	VolitionRx Limited And Sysmex Corporation Announce Collaboration To Optimize Nu.Q NETs H3.1 Assay On Sysmex Platform